Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

SUPN - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.51B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Supernus Pharmaceuticals IncSupernus Pharmaceuticals Inc8.127.36%73%4.2-9.4
$49.00

Target Price by Analysts

64.9% upsideSupernus Pharmaceuticals Target Price DetailsTarget Price
$-1.27

Current Fair Value

104.3% downside

Overvalued by 104.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.51 Billion
Enterprise Value$3.77 Billion
Annual dividend$8.13
Dividend yield27.36%
Earnings per Share$1.68
Beta0.52
Outstanding Shares118,000,000

Return

Return on Equity73.09%ROE
Return on Assets-3.29%
Return on Invested Capital-220.31%

Valuation & Multiples

P/E Ratio8.12P/E Ratio
PEG-5.55PEG
Price to Sales4.25Price to Sales
Price to Book Ratio-29.72Price to Book Ratio
Enterprise Value to Revenue4.35
Enterprise Value to EBIT-55.14
Enterprise Value to Net Income-86
Total Debt to Enterprise0.15
Debt to Equity-9.4Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 10, 2026
EPS Estimate
$0.68
Consensus analyst estimate
Revenue Estimate
$217.79 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 23, 2027
EPS Estimate
$0.99
Consensus analyst estimate
Revenue Estimate
$230.85 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 642.52%
Total Calls671▼ 96.79%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %10.87%▼ 94.16%
Total Invested$327.69M▼ 88.44%
Investors Holding127▼ 213.00%

About Supernus Pharmaceuticals Inc

778 employees
CEO: Jack Khattar

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medica...

Supernus Pharmaceuticals Insider Information FAQ

Stockcircle tracks 8 top investors with a current 13F position in Supernus Pharmaceuticals. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 2 top investors increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 2 open-market insider purchases and 3 open-market insider sales for Supernus Pharmaceuticals in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Stockcircle lists 2 politician trade disclosures tied to Supernus Pharmaceuticals in the last twelve months, drawn from periodic financial disclosure reports. 1 politician traded Supernus Pharmaceuticals in the past year.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.